Full-Time

Associate Specialist

Data Visualization

Posted on 5/12/2025

Deadline 5/27/25
Merck

Merck

10,001+ employees

Develops medicines and vaccines for health issues

No salary listed

Junior, Mid

Hyderabad, Telangana, India + 1 more

More locations: Pune, Maharashtra, India

Category
Data Analysis
Data & Analytics
Required Skills
Power BI
Dataiku
Agile
Redshift
Python
Product Management
SQL
SCRUM
Business Analytics
Databricks
Snowflake
Requirements
  • 2+ years of experience in business intelligence, insight generation, business analytics, data visualization, infographics, and interactive visual storytelling
  • Hands-on expertise in BI and visualization tools such as Power BI, PowerApps, Qliksense, MicroStrategy, and ThoughtSpot
  • Experience of data engineering and modeling, including ETL workflows, Dataiku, Databricks, Informatica, and database technologies like Redshift and Snowflake, with programming skills in SQL and Python
  • Knowledge of pharma commercial data sources, including IQVIA, APLD, Claims, Payer, Salesforce, Financials, Veeva, Komodo, IPSOS, and other industry datasets to drive strategic insights is plus
  • Experience in pharmaceutical commercial analytics, including Field Force Effectiveness, customer engagement, market performance assessment, as well as web, campaign, and digital engagement analytics is plus
  • Experience in agile ways of working, including Agile/Scrum methodologies, iterative development, and continuous improvement in data visualization and analytics solutions
  • Good problem-solving and communication skills, with the ability to interpret data and provide actionable insights while effectively working in cross-functional environments
  • Basic understanding of product management principles, focusing on developing user-centric, scalable analytical solutions aligned with business needs
  • Familiarity with agile ways of working, including exposure to Agile/Scrum methodologies and participation in iterative development and continuous improvement initiatives in data visualization and analytics projects
  • Strong learning agility, with the ability to quickly adapt to new tools, technologies, and business environments while continuously enhancing analytical and technical skills.
Responsibilities
  • Develop user-centric scalable visualization and analytical solutions, leveraging complex data sources to create intuitive and insightful dashboards. Apply best practices in visualization design to enhance user experience and business impact.
  • Collaborating with Data Viz leads and stakeholders to define key metrics, KPIs, and reporting needs. Participate and contribute in workshops to develop user stories, wireframes, and interactive visualizations.
  • Ensuring timely delivery of high-quality outputs, while creating and maintaining SOPs, KPI libraries, and other essential governance documents.
  • Partner with data engineering, data science, and IT teams to develop scalable business-friendly reporting solutions. Ensure adherence to data governance, privacy, and security best practices.
  • Identify opportunities for automation, streamlining manual reporting processes through modern visualization technologies and self-service analytics enablement.
  • Continuously innovative on visualization best practices & technologies by reviewing external resources & marketplace.
Desired Qualifications
  • Knowledge of pharma commercial data sources, including IQVIA, APLD, Claims, Payer, Salesforce, Financials, Veeva, Komodo, IPSOS, and other industry datasets to drive strategic insights is plus
  • Experience in pharmaceutical commercial analytics, including Field Force Effectiveness, customer engagement, market performance assessment, as well as web, campaign, and digital engagement analytics is plus.

Merck develops medicines and vaccines to address major health challenges such as cardiovascular disease, diabetes, and cancer. The company conducts extensive research and development to create new treatments, focusing on the pharmaceutical and biotechnology sectors. Merck generates revenue through the sale of prescription medications, vaccines, and animal health products. A key aspect of Merck's approach is its commitment to patient assistance programs, which provide free medicines and vaccines to eligible patients. Additionally, Merck supports healthcare professionals with resources like Merck Connect and Merck Manuals, setting it apart from competitors by emphasizing both patient care and professional education.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck's $1 billion investment in a vaccine site boosts U.S. manufacturing capabilities.
  • AI-driven drug discovery platforms improve R&D efficiency and success rates.
  • Digital twins in clinical trials enhance trial designs and personalized medicine approaches.

What critics are saying

  • Merck's mumps vaccine fraud damages reputation and trust in vaccine products.
  • Susonity cosmetics brand may divert focus from core pharmaceutical operations.
  • U.S. manufacturing expansion faces financial risks from changing market conditions.

What makes Merck unique

  • Merck's collaboration with Benchling enhances bioanalytical workflows for vaccine development.
  • Merck's AI initiatives accelerate R&D and reduce software development costs.
  • Merck's investment in mRNA technology opens new treatment avenues beyond vaccines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Holidays

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Flexible Work Hours

Company News

Yahoo Finance
Jun 11th, 2025
Benchling Announces Collaboration With Merck On Vaccine Bioanalysis

Unified platform drives bioanalytical capacity, throughput, and efficiency in regulated environment SAN FRANCISCO, June 11, 2025 /PRNewswire/ -- Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a software framework that helps bring Merck's pre-clinical and clinical bioanalytical workflows onto one flexible, fully integrated platform. The collaboration focuses on three key areas: enhancing speed and throughput with automated data capture and integration; streamlining with a unified platform for managing workflows and data across the bioanalytical lifecycle; and maintaining rigorous quality and compliance standards in a regulated bioanalytical setting. "Our work with Merck demonstrates how technology and thoughtful collaboration can help address key scientific needs in bioanalysis," said Sajith Wickramasekara, co-founder and CEO of Benchling. "By focusing on the modern demands of bioanalytical labs, we're delivering an approach that aims to enhance efficiency throughout the vaccine development lifecycle." "Sophisticated data management capabilities are integral to advancing vaccine research and development," said Roy Helmy, Associate Vice President, Regulated Bioanalytics at Merck Research Laboratories. "We're thrilled to collaborate with the team at Benchling on a digital integration that enables our scientists to access, analyze, and harness data insights throughout the development process." About Benchling Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling RD Cloud as their central source of truth for scientific data, analysis, and collaboration

News Channel Nebraska
Jun 4th, 2025
AI Networking Summit Dallas 2025 Breaks Records and Sets the Stage for the Future of AI-Powered Enterprises

Merck's Sean Finnerty was awarded a Community Appreciation Award for sharing how Merck is using AI to speed up and save software development costs.

Personal Care Magazine
May 30th, 2025
Merck reveals launch of Susonity brand for cosmetics

Merck reveals launch of Susonity brand for cosmetics.

MyCentralJersey
May 29th, 2025
NJ drug companies will spend billions to expand in the U.S. Here's what's driving them

Rahway-based drugmaker Merck last month announced plans to spend $1 billion on a vaccine manufacturing site in North Carolina, plus $8 billion on other upgrades by 2028.

Natural News
May 22nd, 2025
Merck's mumps fraud: A 50-year cover-up exposed as vaccine efficacy claims crumble

Merck's mumps vaccine, part of the MMR shots, is confirmed to be far less effective than claimed, with courts acknowledging intentional fraud to maintain monopoly and avoid admitting failure.

INACTIVE